SLC5A2 and type 2 diabetes mellitus: When comparing GLP-1 RAs and SGLT-2 inhibitors to DPP-4 inhibitors, our findings suggest that the benefits of GLP-1 RAs and SGLT-2 inhibitors demonstrated in clinical trials—for patients with T2D and established CV disease, or a high cardiovascular risk profile—may be somewhat lessened in a nationwide population of T2D patients at moderate CV risk.